ProfileGDS5678 / 1422352_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 37% 37% 37% 38% 37% 37% 37% 37% 36% 36% 37% 37% 37% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8728337
GSM967853U87-EV human glioblastoma xenograft - Control 22.8474937
GSM967854U87-EV human glioblastoma xenograft - Control 32.850537
GSM967855U87-EV human glioblastoma xenograft - Control 42.8067138
GSM967856U87-EV human glioblastoma xenograft - Control 52.8074737
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9352737
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8979237
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8347837
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8060136
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8120436
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8366137
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8109937
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.851237
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8431537